Mepolizumab is a humanized monoclonal antibody neutralizing IL-5. Mepolizumab can be used in studies about severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

[accordions]
[accordion title= “References and Literature“]

1. Ian D Pavord, From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. Allergy. 2022 Mar;77(3):778-797.2. Tim Harrison, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151.

[/accordion]